Search

Your search keyword '"Fehm, Tanja"' showing total 2,341 results
Start Over Author "Fehm, Tanja"
2,341 results on '"Fehm, Tanja"'

1. Präoperative Radiotherapie versus postoperative Radiotherapie nach neoadjuvanter Chemotherapie („NeoRad“) beim Hochrisikomammakarzinom: eine prospektive, randomisierte, internationale multizentrische Phase-III-Studie

Author

Matuschek, Christiane, Jazmati, Danny, Krug, David, Corradini, Stefanie, Fehm, Tanja, Ruckhäberle, Eugen, Kühn, Thorsten, Stickeler, Elmar, Nestle-Krämling, Carolin, Holtschmidt, Johannes, Nekljudova, Valentina, Loibl, Sibylle, and Budach, Wilfried

Published
2024
Full Text
View/download PDF

5. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival

Author

Morra, Anna, Schreurs, Maartje AC, Andrulis, Irene L, Anton‐Culver, Hoda, Augustinsson, Annelie, Beckmann, Matthias W, Behrens, Sabine, Bojesen, Stig E, Bolla, Manjeet K, Brauch, Hiltrud, Broeks, Annegien, Buys, Saundra S, Camp, Nicola J, Castelao, Jose E, Cessna, Melissa H, Chang‐Claude, Jenny, Chung, Wendy K, Sahlberg, Kristine K, Børresen‐Dale, Anne‐Lise, Gram, Inger Torhild, Olsen, Karina Standahl, Engebråten, Olav, Naume, Bjørn, Geisler, Jürgen, OSBREAC, Alnæs, Grethe I Grenaker, Colonna, Sarah V, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Daly, Mary B, Dennis, Joe, Devilee, Peter, Dörk, Thilo, Dunning, Alison M, Dwek, Miriam, Easton, Douglas F, Eccles, Diana M, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Fehm, Tanja N, Figueroa, Jonine D, Flyger, Henrik, Gabrielson, Marike, Gago‐Dominguez, Manuela, García‐Closas, Montserrat, García‐Sáenz, José A, Genkinger, Jeanine, Grassmann, Felix, Gündert, Melanie, Hahnen, Eric, Haiman, Christopher A, Hamann, Ute, Harrington, Patricia A, Hartikainen, Jaana M, Hoppe, Reiner, Hopper, John L, Houlston, Richard S, Howell, Anthony, Clarke, Christine, Marsh, Deborah, Scott, Rodney, Baxter, Robert, Yip, Desmond, Carpenter, Jane, Davis, Alison, Pathmanathan, Nirmala, Simpson, Peter, Graham, J Dinny, Sachchithananthan, Mythily, Amor, David, Andrews, Lesley, Antill, Yoland, Balleine, Rosemary, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Burke, Jo, Butow, Phyllis, Caldon, Liz, Campbell, Ian, Cao, Michelle, Chakrabarti, Anannya, Chauhan, Deepa, Chauhan, Manisha, Chenevix‐Trench, Georgia, Christian, Alice, Cohen, Paul, Colley, Alison, Crook, Ashley, Cui, James, Courtney, Eliza, Cummings, Margaret, and Dawson, Sarah‐Jane

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer, Prevention, Clinical Research, Women's Health, Female, Humans, Breast Neoplasms, Checkpoint Kinase 2, Genetic Predisposition to Disease, Germ-Line Mutation, Heterozygote, Proportional Hazards Models, CHEK2 c.1100delC germline genetic variant, contralateral breast cancer risk, radiotherapy, survival, systemic treatment, NBCS Collaborators, ABCTB Investigators, kConFab Investigators, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

BackgroundBreast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers.AimTo assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS.MethodsAnalyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death.ResultsThere was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09-1.56)].ConclusionSystemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.

Published
2023

7. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer

Author

Fasching, Peter A., Hu, Chunling, Hart, Steven N., Ruebner, Matthias, Polley, Eric C., Gnanaolivu, Rohan D., Hartkopf, Andreas D., Huebner, Hanna, Janni, Wolfgang, Hadji, Peyman, Tesch, Hans, Uhrig, Sabrina, Ettl, Johannes, Lux, Michael P., Lüftner, Diana, Wallwiener, Markus, Wurmthaler, Lena A., Goossens, Chloë, Müller, Volkmar, Beckmann, Matthias W., Hein, Alexander, Anetsberger, Daniel, Belleville, Erik, Wimberger, Pauline, Untch, Michael, Ekici, Arif B., Kolberg, Hans-Christian, Hartmann, Arndt, Taran, Florin-Andrei, Fehm, Tanja N., Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Häberle, Lothar, and Couch, Fergus J.

Published
2024
Full Text
View/download PDF

11. Seltene Malignome der Brust

Author

Pervan, Mascha, Princk, Henriette, Meneder, Sabine, Banys-Paluchowski, Maggie, Fehm, Tanja, Ruckhäberle, Eugen, Hanker, Lars, Fitzgerald, Sophia, Rody, Achim, and Krawczyk, Natalia

Published
2024
Full Text
View/download PDF

16. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole

Author

Fasching, Peter A., Hack, Carolin C., Nabieva, Naiba, Maass, Nicolai, Aktas, Bahriye, Kümmel, Sherko, Thomssen, Christoph, Wolf, Christopher, Kolberg, Hans-Christian, Brucker, Cosima, Janni, Wolfgang, Dall, Peter, Schneeweiss, Andreas, Marme, Frederik, Sütterlin, Marc W., Ruebner, Matthias, Theuser, Anna-Katharin, Kellner, Sara, Hofmann, Nadine M., Böhm, Sybille, Almstedt, Katrin, Lück, Hans-Joachim, Schmatloch, Sabine, Kalder, Matthias, Uleer, Christoph, Jurhasz-Böss, Ingolf, Hanf, Volker, Jackisch, Christian, Müller, Volkmar, Rack, Brigitte, Belleville, Erik, Wallwiener, Diethelm, Rody, Achim, Rauh, Claudia, Bayer, Christian M., Uhrig, Sabrina, Goossens, Chloë, Huebner, Hanna, Brucker, Sara Y., Hein, Alexander, Fehm, Tanja N., and Häberle, Lothar

Published
2024
Full Text
View/download PDF

18. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

Author

Li, Shuai, Silvestri, Valentina, Leslie, Goska, Rebbeck, Timothy R, Neuhausen, Susan L, Hopper, John L, Nielsen, Henriette Roed, Lee, Andrew, Yang, Xin, McGuffog, Lesley, Parsons, Michael T, Andrulis, Irene L, Arnold, Norbert, Belotti, Muriel, Borg, Åke, Buecher, Bruno, Buys, Saundra S, Caputo, Sandrine M, Chung, Wendy K, Colas, Chrystelle, Colonna, Sarah V, Cook, Jackie, Daly, Mary B, de la Hoya, Miguel, de Pauw, Antoine, Delhomelle, Hélène, Eason, Jacqueline, Engel, Christoph, Evans, D Gareth, Faust, Ulrike, Fehm, Tanja N, Fostira, Florentia, Fountzilas, George, Frone, Megan, Garcia-Barberan, Vanesa, Garre, Pilar, Gauthier-Villars, Marion, Gehrig, Andrea, Glendon, Gord, Goldgar, David E, Golmard, Lisa, Greene, Mark H, Hahnen, Eric, Hamann, Ute, Hanson, Helen, Hassan, Tiara, Hentschel, Julia, Horvath, Judit, Izatt, Louise, Janavicius, Ramunas, Jiao, Yue, John, Esther M, Karlan, Beth Y, Kim, Sung-Won, Konstantopoulou, Irene, Kwong, Ava, Laugé, Anthony, Lee, Jong Won, Lesueur, Fabienne, Mebirouk, Noura, Meindl, Alfons, Mouret-Fourme, Emmanuelle, Musgrave, Hannah, Yie, Joanne Ngeow Yuen, Niederacher, Dieter, Park, Sue K, Pedersen, Inge Sokilde, Ramser, Juliane, Ramus, Susan J, Rantala, Johanna, Rashid, Muhammad U, Reichl, Florian, Ritter, Julia, Rump, Andreas, Santamariña, Marta, Saule, Claire, Schmidt, Gunnar, Schmutzler, Rita K, Senter, Leigha, Shariff, Saba, Singer, Christian F, Southey, Melissa C, Stoppa-Lyonnet, Dominique, Sutter, Christian, Tan, Yen, Teo, Soo Hwang, Terry, Mary Beth, Thomassen, Mads, Tischkowitz, Marc, Toland, Amanda E, Torres, Diana, Vega, Ana, Wagner, Sebastian A, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weber, Bernhard HF, Yannoukakos, Drakoulis, Spurdle, Amanda B, Easton, Douglas F, and Chenevix-Trench, Georgia

Subjects
Ovarian Cancer, Cancer, Urologic Diseases, Breast Cancer, Prevention, Digestive Diseases, Aging, Rare Diseases, Aetiology, 2.1 Biological and endogenous factors, BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Breast Neoplasms, Male, Female, Genetic Predisposition to Disease, Heterozygote, Humans, Infant, Newborn, Male, Mutation, Ovarian Neoplasms, Pancreatic Neoplasms, Risk, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management.MethodsWe used data from 3,184 BRCA1 and 2,157 BRCA2 families in the Consortium of Investigators of Modifiers of BRCA1/2 to estimate age-specific relative (RR) and absolute risks for 22 first primary cancer types adjusting for family ascertainment.ResultsBRCA1 PVs were associated with risks of male breast (RR = 4.30; 95% CI, 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach (RR = 2.17; 95% CI, 1.25 to 3.77) cancers. Associations with colorectal and gallbladder cancers were also suggested. BRCA2 PVs were associated with risks of male breast (RR = 44.0; 95% CI, 21.3 to 90.9), stomach (RR = 3.69; 95% CI, 2.40 to 5.67), pancreatic (RR = 3.34; 95% CI, 2.21 to 5.06), and prostate (RR = 2.22; 95% CI, 1.63 to 3.03) cancers. The stomach cancer RR was higher for females than males (6.89 v 2.76; P = .04). The absolute risks to age 80 years ranged from 0.4% for male breast cancer to approximately 2.5% for pancreatic cancer for BRCA1 carriers and from approximately 2.5% for pancreatic cancer to 27% for prostate cancer for BRCA2 carriers.ConclusionIn addition to female breast and ovarian cancers, BRCA1 and BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, and prostate (only BRCA2 PVs) cancers, but not with the risks of other previously suggested cancers. The estimated age-specific risks will refine cancer risk management in men and women with BRCA1/2 PVs.

Published
2022

19. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

Author

Fehm, Tanja, Cottone, Francesco, Dunton, Kyle, André, Fabrice, Krop, Ian, Park, Yeon Hee, De Laurentiis, Michelino, Miyoshi, Yasuo, Armstrong, Anne, Borrego, Manuel Ruiz, Yerushalmi, Rinat, Duhoux, Francois P, Takano, Toshimi, Lu, Wenjing, Egorov, Anton, and Kim, Sung-Bae

Published
2024
Full Text
View/download PDF

20. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis

Author

Stoecklein, Nikolas H., Fluegen, Georg, Guglielmi, Rosa, Neves, Rui P.L., Hackert, Thilo, Birgin, Emrullah, Cieslik, Stefan A., Sudarsanam, Monica, Driemel, Christiane, van Dalum, Guus, Franken, André, Niederacher, Dieter, Neubauer, Hans, Fehm, Tanja, Rox, Jutta M., Böhme, Petra, Häberle, Lena, Göring, Wolfgang, Esposito, Irene, Topp, Stefan A., Coumans, Frank A.W., Weitz, Jürgen, Knoefel, Wolfram T., Fischer, Johannes C., Bork, Ulrich, and Rahbari, Nuh N.

Published
2023
Full Text
View/download PDF

22. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy

Author

Wimberger, Pauline, Blohmer, Jens-Uwe, Krabisch, Petra, Link, Theresa, Just, Marianne, Sinn, Bruno Valentin, Simon, Eike, Solbach, Christine, Fehm, Tanja, Denkert, Carsten, Kühn, Cristin, Rhiem, Kerstin, Tesch, Hans, Kümmel, Sherko, Petzold, Andrea, Stötzer, Oliver, Meisel, Cornelia, Kuhlmann, Jan Dominik, Nekljudova, Valentina, and Loibl, Sibylle

Published
2023
Full Text
View/download PDF

23. Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value

Author

Franken, André, Kraemer, Annika, Sicking, Alicia, Watolla, Meike, Rivandi, Mahdi, Yang, Liwen, Warfsmann, Jens, Polzer, Bernhard M., Friedl, Thomas W. P., Meier-Stiegen, Franziska, Stoecklein, Nikolas H., Dayan, Davut, Riethdorf, Sabine, Mueller, Volkmar, Pantel, Klaus, Koch, André, Hartkopf, Andreas D., Krawczyk, Natalia, Ruckhaeberle, Eugen, Niederacher, Dieter, Fehm, Tanja, and Neubauer, Hans

Published
2023
Full Text
View/download PDF

26. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

Author

Fasching, Peter A., Decker, Thomas, Hartkopf, Andreas, Nusch, Arnd, Heinrich, Bernhard J., Kurbacher, Christian, Fuchs, Roswitha, Tesch, Hans, Krabisch, Petra, Huober, Jens, Kuemmel, Sherko, Brucker, Sara, Janni, Wolfgang, Schneeweiss, Andreas, Schuler, Martin, Fehm, Tanja, Lüftner, Diana, Quiering, Claudia, Voges, Claudia, Kreuzeder, Julia, and Reinisch, Mattea

Published
2024
Full Text
View/download PDF

27. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

33. Return of individual genomic research results within the PRAEGNANT multicenter registry study

Author

Huebner, Hanna, Ruebner, Matthias, Kurbacher, Christian, Hadji, Peyman, Hartkopf, Andreas D., Lux, Michael P., Huober, Jens, Uhrig, Sabrina, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Hein, Alexander, Belleville, Erik, Untch, Michael, Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Ettl, Johannes, Fasching, Peter A., and Michel, Laura L.

Published
2023
Full Text
View/download PDF

34. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Author

Magbanua, Mark Jesus M, Hendrix, Laura H, Hyslop, Terry, Barry, William T, Winer, Eric P, Hudis, Clifford, Toppmeyer, Deborah, Carey, Lisa Anne, Partridge, Ann H, Pierga, Jean-Yves, Fehm, Tanja, Vidal-Martínez, José, Mavroudis, Dimitrios, Garcia-Saenz, Jose A, Stebbing, Justin, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, Antelo, María Luisa, De Mattos-Arruda, Leticia, Generali, Daniele, Caldas, Carlos, Munzone, Elisabetta, Dirix, Luc, Delson, Amy L, Burstein, Harold J, Qadir, Misbah, Ma, Cynthia, Scott, Janet H, Bidard, François-Clément, Park, John W, and Rugo, Hope S

Subjects
Cancer, Prevention, Breast Cancer, Clinical Research, Breast Neoplasms, Female, Humans, Neoplastic Cells, Circulating, Prognosis, Progression-Free Survival, Proportional Hazards Models, Reproducibility of Results, Retrospective Studies, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundWe examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.MethodsSerial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.ResultsLatent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.ConclusionsWe identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.

Published
2021

35. Impact of surgical variables on residual glandular tissue in risk-reducing mastectomies: Results of a retrospective monocentric study from a center of the German consortium for hereditary breast and ovarian cancer

Author

Mohrmann, Svjetlana, Kolberg, Leoni, Jäger, Bernadette, Hoffmann, Jürgen, Nestle-Krämling, Carolin, Zwiefel, Karin, Friebe, Verena, Sawicki, Lino M., Bruckmann, Nils Martin, Jannusch, Kai, Morawitz, Janna, Antoch, Gerald, Fehm, Tanja Natascha, Kirchner, Julian, and Dietzel, Frederic

Published
2023
Full Text
View/download PDF

37. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard, Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., and Schmidt, M.

Published
2023
Full Text
View/download PDF

40. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Author

André, Fabrice, Hee Park, Yeon, Kim, Sung-Bae, Takano, Toshimi, Im, Seock-Ah, Borges, Giuliano, Lima, Joao Paulo, Aksoy, Sercan, Gavila Gregori, Joaquin, De Laurentiis, Michelino, Bianchini, Giampaolo, Roylance, Rebecca, Miyoshi, Yasuo, Armstrong, Anne, Sinha, Rajni, Ruiz Borrego, Manuel, Lim, Elgene, Ettl, Johannes, Yerushalmi, Rinat, Zagouri, Flora, Duhoux, Francois P, Fehm, Tanja, Gambhire, Dhiraj, Cathcart, Jillian, Wu, Cai, Chu, Changan, Egorov, Anton, and Krop, Ian

Published
2023
Full Text
View/download PDF

41. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

Author

Fasching, Peter A., Hein, Alexander, Kolberg, Hans-Christian, Häberle, Lothar, Uhrig, Sabrina, Rübner, Matthias, Belleville, Erik, Hack, Carolin C., Fehm, Tanja N., Janni, Wolfang, Hartmann, Arndt, Erber, Ramona, Theuser, Anna-Katharin, Brucker, Sara Y., Hartkopf, Andreas D., and Untch, Michael

Published
2023
Full Text
View/download PDF

45. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials

Author

Jank, Paul, primary, Karn, Thomas, additional, van Mackelenbergh, Marion, additional, Lindner, Judith, additional, Treue, Denise, additional, Huober, Jens, additional, Engels, Knut, additional, Solbach, Christine, additional, Diebold, Kurt, additional, Marme, Frederik, additional, Müller, Volkmar, additional, Schneeweiss, Andreas, additional, Sinn, Hans-Peter, additional, Fehm, Tanja, additional, Schem, Christian, additional, Stickeler, Elmar, additional, Fasching, Peter A., additional, Budczies, Jan, additional, Felder, Bärbel, additional, Nekljudova, Valentina, additional, Holtschmidt, Johannes, additional, Untch, Michael, additional, Denkert, Carsten, additional, and Loibl, Sibylle, additional

Published
2024
Full Text
View/download PDF

46. The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.

Author

Pfister, Kerstin, primary, Huesmann, Sophia, additional, Friedl, Thomas W. P., additional, Fink, Angelina, additional, Mehmeti, Forca, additional, Mergel, Franziska, additional, Schäffler, Henning, additional, Heublein, Sabine, additional, Hartkopf, Andreas Daniel, additional, Mueller, Volkmar, additional, Wiesmueller, Lisa Maria, additional, Fehm, Tanja N., additional, Pantel, Klaus, additional, Rack, Brigitte, additional, and Janni, Wolfgang, additional

Published
2024
Full Text
View/download PDF

47. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Author

Würstlein, Rachel, additional, Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Krückel, Annika, additional, Belleville, Erik, additional, Lüftner, Diana, additional, Untch, Michael, additional, Thill, Marc, additional, Hörner, Manuel, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Taran, Florin-Andrei, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, and Müller, Volkmar, additional

Published
2024
Full Text
View/download PDF

49. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

Author

Hein, Alexander, primary, Fasching, Peter A., primary, Hack, Carolin C., additional, Maass, Nicolai, additional, Aktas, Bahriye, additional, Kümmel, Sherko, additional, Thomssen, Christoph, additional, Wolf, Christopher, additional, Kolberg, Hans-Christian, additional, Brucker, Cosima, additional, Janni, Wolfgang, additional, Dall, Peter, additional, Schneeweiss, Andreas, additional, Marme, Frederik, additional, Ruebner, Matthias, additional, Theuser, Anna-Katharin, additional, Hofmann, Nadine M., additional, Böhm, Sybille, additional, Almstedt, Katrin, additional, Kellner, Sara, additional, Nabieva, Naiba, additional, Gass, Paul, additional, Sütterlin, Marc W., additional, Lück, Hans-Joachim, additional, Schmatloch, Sabine, additional, Kalder, Matthias, additional, Uleer, Christoph, additional, Juhasz-Böss, Ingolf, additional, Hanf, Volker, additional, Jackisch, Christian, additional, Müller, Volkmar, additional, Rack, Brigitte, additional, Belleville, Erik, additional, Wallwiener, Diethelm, additional, Rody, Achim, additional, Rauh, Claudia, additional, Bayer, Christian M., additional, Uhrig, Sabrina, additional, Goossens, Chloë, additional, Huebner, Hanna, additional, Brucker, Sara Y., additional, Häberle, Lothar, additional, and Fehm, Tanja N., additional

Published
2024
Full Text
View/download PDF

50. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

Author

Schneeweiss, Andreas, additional, Brucker, Sara Y., additional, Huebner, Hanna, additional, Volmer, Lea L., additional, Hack, Carolin C., additional, Seitz, Katharina, additional, Ruebner, Matthias, additional, Heublein, Sabine, additional, Thewes, Verena, additional, Lüftner, Diana, additional, Lux, Michael P., additional, Jurhasz-Böss, Ingolf, additional, Taran, Florin-Andrei, additional, Wimberger, Pauline, additional, Anetsberger, Daniel, additional, Beierlein, Milena, additional, Schmidt, Marcus, additional, Radosa, Julia, additional, Müller, Volkmar, additional, Janni, Wolfgang, additional, Rack, Brigitte, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Nel, Ivonne, additional, Kolberg, Hans-Christian, additional, Engerle, Tobias, additional, Tesch, Hans, additional, Roos, Christian, additional, Budden, Christina, additional, Neubauer, Hans, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, and Fasching, Peter A., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results